Abstract
Recent data might subtly recalibrate the risk/benefit ratio of lithium, the prototypical mood stabiliser for bipolar disorder. There are hints that lithium might be associated with a reduction in dementia risk and as noted in this Journal, a surprising reduction in the risk of cancer.
© The Royal College of Psychiatrists 2017.
Publication types
-
Editorial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antimanic Agents / therapeutic use
-
Bipolar Disorder / drug therapy
-
Dementia / drug therapy*
-
Humans
-
Lithium Compounds / adverse effects
-
Lithium Compounds / therapeutic use*
-
Neoplasms / chemically induced*
Substances
-
Antimanic Agents
-
Lithium Compounds